Abstract
In the last decade, new drugs for multiple sclerosis have been tested and approved. Among them is natalizumab, that despite its high efficacy has its use limited by the risk of developing progressive multifocal leukoencephalopathy. By applying, a questionnaire with inclusion of patients diagnosed with relapsing-remitting multiple sclerosis, we aimed to assess how patients assess the risks…